Edward Greeno, MD
Medical Oncology · Minneapolis, MNNPI 1386670297
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Incyte Corporation. That places this record below the midpoint for medical oncology clinicians in MN, where the typical reported total is $1,006.
Across 1 payment — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$21
Across 11 payments — averaging $37,728 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Anaeropahrma Science, Inc.$247K
- E.r. Squibb & Sons, L.L.C.$119K
- Halozyme Inc$23K
- Incyte Corporation$10K
- Ipsen Bioscience Inc.$9K
- Astellas Pharma Global Development$7K
What the payments were for
- Food & beverage$21100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 1 | $21 |
How this compares
$21 in reported general payments places this provider in the 10th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LonsurfTrifluridine/Tipiracil Hcl | 21 | $444,068 |
| LenvimaLenvatinib Mesylate | 11 | $251,436 |
| CreonLipase/Protease/Amylase | 28 | $113,789 |
| GleevecImatinib Mesylate | 12 | $96,362 |
| SorafenibSorafenib Tosylate | 14 | $85,537 |
| XareltoRivaroxaban | 28 | $23,589 |
| EliquisApixaban | 17 | $11,083 |
| Imatinib Mesylate | 38 | $9,499 |
| LoperamideLoperamide Hcl | 27 | $546 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $426 |
| Prochlorperazine Maleate | 35 | $418 |
| Ondansetron Hcl | 44 | $316 |
| Potassium Chloride | 13 | $230 |
| Oxycodone Hcl | 14 | $189 |
| Gabapentin | 13 | $166 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Minneapolis
- Amy KrieMinneapolis$907K
- Emmanuel AntonarakisMinneapolis$260K
- Charles RyanMinneapolis$99K
- Dean GesmeMinneapolis$92K
- Robert KratzkeMinneapolis$79K
- Evidio Domingo MusibayMinneapolis$38K
- Emil LouMinneapolis$11K
- Keith SkubitzMinneapolis$5K
- Alexandra RezazadehMinneapolis$3K
- Matthew NwaneriMinneapolis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.